BEIGENE's Q1 loss narrowed to 94.503 million yuan, with Baiyueze and Baizean sales revenue increasing.
In the first quarter of 2025, BEIGENE achieved revenue of 8.048 billion yuan, a year-on-year increase of 50.2%; the net income attributable to the parent was a loss of 94.503 million yuan, compared to a loss of 1.908 billion yuan in the same period last year; In recent years, with policy support, China's Innovative Drugs Industry has entered a period of rapid development. In 2024, the industry will usher in a new round of policy dividends, and the research and development results of domestic Innovative Drugs will experience explosive growth.
BeiGene Issues New Shares to Support Equity Awards and Growth Plans
BEIGENE (06160) plans to allocate and issue 0.133 billion new shares to BGNC2 according to the 2016 plan.
BEIGENE (06160) announced that on December 7, 2018, the company's Shareholders approved the second revised and...
Earnings Preview: BeiGene
BEIGENE (688235.SH) reported a revenue of 8.048 billion yuan in the first quarter, a year-on-year increase of 50.2%.
BEIGENE (688235.SH) released the first quarter report for 2025, with the company's revenue in the first quarter being 80....
BeiGene to Present at the RBC Capital Markets Global Healthcare Conference
